NASDAQ:RLMD Relmada Therapeutics (RLMD) Stock Price, News & Analysis → Bigger Than NVIDIA? (From Behind the Markets) (Ad) Free RLMD Stock Alerts $3.00 -0.01 (-0.33%) (As of 06/17/2024 ET) Add Compare Share Share Today's Range$2.98▼$3.0450-Day Range$2.93▼$4.8052-Week Range$2.36▼$7.22Volume68,181 shsAverage Volume201,482 shsMarket Capitalization$90.51 millionP/E RatioN/ADividend YieldN/APrice Target$13.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Relmada Therapeutics alerts: Email Address Relmada Therapeutics MarketRank™ Stock AnalysisAnalyst RatingSell1.00 Rating ScoreUpside/Downside350.0% Upside$13.50 Price TargetShort InterestBearish5.10% of Shares Sold ShortDividend StrengthN/ASustainability-1.45Upright™ Environmental ScoreNews Sentiment0.89Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.04) to ($2.94) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.90 out of 5 starsMedical Sector378th out of 913 stocksPharmaceutical Preparations Industry173rd out of 429 stocks 2.5 Analyst's Opinion Consensus RatingRelmada Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageRelmada Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Relmada Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.10% of the outstanding shares of Relmada Therapeutics have been sold short.Short Interest Ratio / Days to CoverRelmada Therapeutics has a short interest ratio ("days to cover") of 11.1, which indicates bearish sentiment.Change versus previous monthShort interest in Relmada Therapeutics has recently decreased by 1.91%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldRelmada Therapeutics does not currently pay a dividend.Dividend GrowthRelmada Therapeutics does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRelmada Therapeutics has received a 66.71% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Clinical research services for mood disorders" product. See details.Environmental SustainabilityThe Environmental Impact score for Relmada Therapeutics is -1.45. Previous Next 2.7 News and Social Media Coverage News SentimentRelmada Therapeutics has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Relmada Therapeutics this week, compared to 1 article on an average week.MarketBeat Follows3 people have added Relmada Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Relmada Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders18.00% of the stock of Relmada Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions45.24% of the stock of Relmada Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Relmada Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Relmada Therapeutics are expected to grow in the coming year, from ($3.04) to ($2.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Relmada Therapeutics is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Relmada Therapeutics is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRelmada Therapeutics has a P/B Ratio of 1.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Relmada Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsThe Military's $700M "AI Software Bullet"The Pentagon is spending over $700 MILLION on a top-secret project called "Overmatch." It's a software-defined networking solution that will connect all sensors, weapons, platforms, and personnel across our military branches.Get the name and stock ticker of this critical military tech firm HERE>>> About Relmada Therapeutics Stock (NASDAQ:RLMD)Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.Read More RLMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RLMD Stock News HeadlinesJune 10, 2024 | prnewswire.comRelmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceJune 3, 2024 | prnewswire.comRelmada Therapeutics to Participate in the 2024 Jefferies Global Healthcare ConferenceMay 28, 2024 | investorplace.com7 Penny Biotech Stocks to Triple Your InvestmentMay 27, 2024 | finance.yahoo.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2024 Earnings Call TranscriptMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Relmada Therapeutics on Strong Clinical Trials and Financial FootingMay 10, 2024 | markets.businessinsider.comBuy Rating for Relmada Therapeutics Supported by Strong Clinical Pipeline and Financial StabilityMay 9, 2024 | finance.yahoo.comQ1 2024 Relmada Therapeutics Inc Earnings CallMay 8, 2024 | msn.comRLMD Stock Earnings: Relmada Therapeutics Beats EPS for Q1 2024May 8, 2024 | prnewswire.comRelmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 6, 2024 | prnewswire.comRelmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024April 16, 2024 | finance.yahoo.comRELMADA THERAPEUT.DL-,001 (4E2.F)March 21, 2024 | seekingalpha.comRelmada Therapeutics: Run Up Into Results May Resume Following This DropMarch 21, 2024 | markets.businessinsider.comOptimistic Buy Rating for Relmada Therapeutics Amidst Strong Phase 3 Trial Prospects and Financial StabilityMarch 20, 2024 | finance.yahoo.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2023 Earnings Call TranscriptMarch 20, 2024 | finanznachrichten.deRelmada Therapeutics, Inc.: Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial ResultsMarch 20, 2024 | finance.yahoo.comQ4 2023 Relmada Therapeutics Inc Earnings CallMarch 19, 2024 | investorplace.comRLMD Stock Earnings: Relmada Therapeutics Misses EPS for Q4 2023March 19, 2024 | benzinga.comRecap: Relmada Therapeutics Q4 EarningsMarch 19, 2024 | finance.yahoo.comRelmada Therapeutics Inc Reports Full-Year and Q4 2023 Financial ResultsMarch 19, 2024 | prnewswire.comRelmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial ResultsMarch 19, 2024 | msn.comOptions Volatility and Implied Earnings Moves Today, March 19, 2024March 18, 2024 | msn.comRelmada Therapeutics FY 2023 Earnings PreviewMarch 16, 2024 | finance.yahoo.comRLMD Apr 2024 2.500 putMarch 5, 2024 | prnewswire.comRelmada Therapeutics to Participate in the Leerink Partners Global Biopharma ConferenceFebruary 13, 2024 | investing.comRelmada Therapeutics Inc (RLMD)See More Headlines Receive RLMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Relmada Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today6/17/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RLMD CUSIPN/A CIK1553643 Webwww.relmada.com Phone(786) 629-1376FaxN/AEmployees20Year Founded2004Price Target and Rating Average Stock Price Target$13.50 High Stock Price Target$25.00 Low Stock Price Target$2.00 Potential Upside/Downside+350.0%Consensus RatingSell Rating Score (0-4)1.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-98,790,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-102.09% Return on Assets-91.30% Debt Debt-to-Equity RatioN/A Current Ratio6.82 Quick Ratio6.82 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.84 per share Price / Book1.06Miscellaneous Outstanding Shares30,170,000Free Float24,743,000Market Cap$90.51 million OptionableOptionable Beta0.40 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Sergio Traversa M.B.A. (Age 64)Pharm.D., CEO & Director Comp: $1.79MMr. Maged S. Shenouda M.B.A. (Age 60)R.Ph., Chief Financial Officer Comp: $1.01MMr. Charles S. Ence CPA (Age 59)M.B.A., Chief Accounting & Compliance Officer Comp: $995.03kDr. Paolo Manfredi M.D. (Age 62)Ph.D., Chief Scientific Officer Ms. Gina DiGuglielmoVP & Head of Clinical OperationsDr. Marco Pappagallo M.D. (Age 65)Chief Clinical Officer Mr. John HixonHead of CommercialDr. Andrew CutlerSenior Clinical Development AdvisorDr. Richard M. Mangano (Age 74)Consultant More ExecutivesKey CompetitorsZIOPHARM OncologyNASDAQ:ZIOPVanda PharmaceuticalsNASDAQ:VNDAVerrica PharmaceuticalsNASDAQ:VRCAOrganogenesisNASDAQ:ORGOXeris BiopharmaNASDAQ:XERSView All CompetitorsInsiders & InstitutionsOpaleye Management Inc.Sold 118,000 shares on 5/29/2024Ownership: 2.516%Jacobs Levy Equity Management Inc.Sold 87,704 shares on 5/16/2024Ownership: 0.417%Vanguard Group Inc.Sold 54,100 shares on 5/10/2024Ownership: 4.165%State Board of Administration of Florida Retirement SystemBought 15,100 shares on 5/9/2024Ownership: 0.050%SG Americas Securities LLCBought 11,320 shares on 5/7/2024Ownership: 0.038%View All Insider TransactionsView All Institutional Transactions RLMD Stock Analysis - Frequently Asked Questions Should I buy or sell Relmada Therapeutics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Relmada Therapeutics in the last twelve months. There are currently 1 sell rating for the stock. The consensus among Wall Street analysts is that investors should "sell" RLMD shares. View RLMD analyst ratings or view top-rated stocks. What is Relmada Therapeutics' stock price target for 2024? 1 analysts have issued 1-year target prices for Relmada Therapeutics' stock. Their RLMD share price targets range from $2.00 to $25.00. On average, they predict the company's share price to reach $13.50 in the next twelve months. This suggests a possible upside of 350.0% from the stock's current price. View analysts price targets for RLMD or view top-rated stocks among Wall Street analysts. How have RLMD shares performed in 2024? Relmada Therapeutics' stock was trading at $4.14 at the beginning of 2024. Since then, RLMD shares have decreased by 27.5% and is now trading at $3.00. View the best growth stocks for 2024 here. When is Relmada Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our RLMD earnings forecast. How were Relmada Therapeutics' earnings last quarter? Relmada Therapeutics, Inc. (NASDAQ:RLMD) issued its quarterly earnings results on Wednesday, May, 8th. The company reported ($0.72) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.18. What ETF holds Relmada Therapeutics' stock? AdvisorShares Psychedelics ETF holds 107,022 shares of RLMD stock, representing 5.33% of its portfolio. Who are Relmada Therapeutics' major shareholders? Relmada Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.17%), Parsons Capital Management Inc. RI (3.23%), Opaleye Management Inc. (2.52%), Guild Investment Management Inc. (0.63%), Jacobs Levy Equity Management Inc. (0.42%) and GSA Capital Partners LLP (0.34%). Insiders that own company stock include Cedric O'gorman, Charles J Casamento, Chuck Ence, Maged Shenouda, Paul Edward Kelly and Sergio Traversa. View institutional ownership trends. How do I buy shares of Relmada Therapeutics? Shares of RLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RLMD) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredUnexpected twist to Trump’s trialUnexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredInflation Is Robbing You Blind! Here’s How to Fight Back!Quietly, inflation has reduced your purchasing power by 29.4% since 2014. So something that cost $100 in 20...American Alternative | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in sev...Chaikin Analytics | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relmada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relmada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.